Insulet, a medical device maker that has developed a highly integrated insulin infusion system for diabetes patients, priced 7.7 million shares (1 million shares more than expected) at $15, the mid-point of its proposed $14-$16 range. Merrill Lynch and JP Morgan jointly managed the books for this offering, and the stock will begin trading on the Nasdaq under the ticker symbol "PODD" on Tuesday.
